Klox Technologies announces positive top-line results from a pivotal study of Phovia(TM) for the management of Canine Deep Pyoderma
DUBLIN, Ireland, July 02, 2018 (GLOBE NEWSWIRE) -- Klox Technologies Limited, a subsidiary of Klox Technologies Inc. ('KTI') has announced they have completed a pivotal study of Phovia for the management of Canine Deep Pyoderma. The 80-patient study met all endpoints and demonstrated that Phovia significantly reduces time to clinical resolution while reducing the duration of antibiotic use.
Phovia is a first-in-class, topical fluorescence biomodulating product, using proprietary technology, to engage inherent biological systems.
This prospective, randomized, controlled, blinded study compared the current standard of care (systemic antibiotic therapy) versus the standard of care plus Phovia twice weekly, until clinical resolution was achieved.
Phovia demonstrated efficacy for the primary endpoint, with the proportion of patients reaching clinical resolution at six (6) weeks being 26.5% for the control group and 84.6% for the Phovia treated group (p<0.001). The statistically significant differences between the two (2) groups were obtained as soon as week three (3). For the secondary endpoints, the Phovia treated group showed a statistically significant reduction of clinical scores, and an improvement in neutrophil engulfing bacteria scores. An exploratory endpoint demonstrated that the median time to clinical resolution for the control group was 12.7 weeks while the Phovia treated group was 4.0 weeks; a significant reduction in treatment times. No product related adverse events were recorded.
Prof. Andrea Spaterna from the University of Camerino, Italy, and principal investigator of the Phovia study, stated that, "Reducing the treatment time of deep pyodermas to this extent is tremendous news for veterinarians, patients and owners alike. A critical part of the results includes reducing the duration of systemic antibiotic use, as it is becoming abundantly clear in the international community that long-term antibiotic use has a high risk factor for the development of antibiotic resistant bacteria."
Investigators strongly believe that a product like Phovia is ready for the veterinary market, as veterinarians and pet owners are more reluctant to treat patients with long-term antibiotics. "I am finding most pet owners are really open to innovative therapies like Phovia, and having the patients come into the clinic for treatment allows for better monitoring of deep pyodermas", concluded Prof. Spaterna.
Klox is advancing discussions with potential partners to bring Phovia, and its pipeline products to market. Partnerships are expected to be announced later this year, and Phovia is anticipated to be commercially available in Europe during H1 2019.
Phovia is a first-in-class, topical fluorescence biomodulating product, using proprietary technology, to engage inherent biological systems. It is based on Klox's patented Fluorescence Biomodulation technology platform, which is a non-invasive, non-thermal technology targeted to improve the management of serious skin/soft tissue disorders for companion animals and horses. It is intended to create an environment that promotes accelerated healing of pyoderma lesions in dogs and promotes wound healing in dogs, cats and horses.
About Canine Deep Pyoderma
Canine deep pyoderma (CDP) is a difficult to treat skin disease in small animals1 characterized by dissemination of bacteria into the deep dermis and/or bacterial infection of the panniculus. The causative organism is Staphylococcus pseudintermedius(formerly S. intermedius) in the vast majority of cases. Bacteria in lesions of deep pyoderma are often located in the center of fibrotic or inflammatory foci, associated with chronic diseases and scarring. Recurrence of the disease is frequent, which requires long-term systemic antibiotic use, and an additional one to two (2) weeks of extended antibiotic use post clinical resolution to ensure complete microbiological remission2,3.
About Klox Technologies
Klox Technologies Inc. is a private biomedical technology innovator, advancing the development and commercialization of its flagship fluorescence generating technology for specific skin/soft tissue conditions and diseases. With franchises in wound care, dermatology, veterinary and oral health, Klox is well positioned to capitalize on significant market opportunities. For more information please visit www.kloxtechnologies.com
Klox Technologies Limited
Dr. Ricardo Garvao, Head of Animal Health
+353 (0) 1 7006216
- Lund EM, Armstrong PJ, Kirk CA et al. Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. Journal of the American Animal Hospital Association 1999; 214: 1336-41.
- Scott DW, Miller WH Jr, Griffin CE. Muller and Kirk's Small Animal Dermatology, 6th edn, ed. Philadelphia: W.B. Saunders, 2001; 453-7.
- Spaterna A. Dermatosi a carattere pustoloso e/o foruncoloso. In: Spaterna A. Dermatologia del cane, dal segno clinico alla diagnosi e terapia, Point Vet. Italie Ed., Milano, 2008; 139-170.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Klox Technologies, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Service Providers Speed Deployment, Reduce Costs with Patton Cloud Edge Orchestration Service20.9.2018 22:16 | Pressemelding
Now, Telecom and UCaaS service providers can easily provision, manage, monitor, secure, alert, troubleshoot, analyze, and optimize services on the customer premise GAITHERSBURG, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—US-manufacturer of UC, cloud, and IoT-enabling solutions for carrier, enterprise, and industrial networks—has launched the new Patton Cloud service for carriers and service providers that deliver All-IP and hybrid voice-and-data services to business subscribers. Patton Cloud delivers a low-cost, easy-to-use, web-based edge-orchestration service that delivers a superior user experience. It offers remote touchless provisioning, monitoring, and troubleshooting—as well as security and alerting tools that reduce service turn-up costs, trouble tickets, and subscriber attrition. The Patton Cloud service offers quality-control mechanisms including pro-active monitoring and troubleshooting—combined with feature-license distribution pools for managing value-added
Inspirata Promotes Top Executives to Expanded Roles in Digital Pathology20.9.2018 21:12 | Pressemelding
Inspirata Founder and Executive Vice President, Mark Lloyd, is taking on an expanded role overseeing product management, and Inspirata Senior Vice President, Andrew Chomos, has been appointed to General Manager, Digital Pathology, overseeing the Center of Excellence in Pittsburgh along with all North America sales and customer support efforts. Tampa, FL, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that two of its executives have taken on expanded roles in the company. The two are Inspirata Executive Vice President and Founder, Mark Lloyd, and Senior Vice President and General Manager, Digital Pathology, Andrew Chomos. Dr. Lloyd has accepted the expansion of his role to include product management for Digital Pathology. He is former cancer researcher at both Lombardi Cancer and Moffitt Cancer Center and is Inspirata’s foremost subject matter expert and thought leader on digital pathology and image
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections20.9.2018 19:08 | Pressemelding
– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the European Commission (EC) has adopted the Decision granting marketing authorisation for XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem. “The European approval of XERAVA, right after our recently announced FDA approval, marks our second significant regulatory approval within one month
UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule20.9.2018 18:07 | Pressemelding
RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory equipment to federal, state, and local governments on contract with the GSA (General Services Administration). By having Taconic’s products available via GSS, they can now be accessed by all federal agencies, including but not limited to the National Institutes of Health and the Department of Defense. Taconic is the only animal model provider affiliated with GSS and the only animal model provider available on GSA Contract. “An important component of providing customers with the best animal model solutions is access to key resources. Through this exciting new relationship with GSS, Taconic can now easily connect with scientists doing some of the most valuable research in the world and provide them with high quality sol
Digital Transformation is Not a One-Off — It’s About the Digital Journey20.9.2018 17:44 | Pressemelding
SoftServe study confirms four digital journey states with 71 percent of enterprises reporting early stages of adoption AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, today released the results of its market research study that examines how enterprises are responding to the digital economy. The research found that 71 percent of the respondents in the United States and the European Union are in the early stages—Reveal and Transform—of four unique states across the Enterprise Digital Journey. For an in-depth analysis and the full results, read The Enterprise Digital Journey white paper. With fierce competition in today’s global landscape, leveraging cutting-edge technology and deploying new business models is not a one-off pursuit, but rather a continuous process of iteration and refinement. Companies should stop referring to Digital Transformation and instead plan for a continuous Digital Journey. “The term Digital Transfo
Anomali Announces Major Expansion of Threat Platform Partner Ecosystem20.9.2018 16:00 | Pressemelding
New Developer SDKs enable partners to integrate solutions with Anomali Threat Platform NATIONAL HARBOR, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Anomali today announced at the Detect Conference 2018 the expansion of the partner ecosystem with the launch of a suite of partner developer resources. The new tools enable easier and faster integration with the Anomali Threat Platform and APP Store, allowing clients immediate access to partner content, integrations and analytics. The partner program expansion includes the launch of a suite of software development kits (SDKs). The SDKs address three critical integration areas: Threat Intelligence Feeds SDK: integrate proprietary threat intelligence feeds and make these accessible via the APP Store Integration SDK: integrate threat intelligence from the Anomali Threat Platform into third party products and solutions Enrichment SDK: integrate 3rd party threat analysis and data enrichments into the Anomali Threat Platform “Organizations need a com
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom